Tempest Therapeutics Inc (OQ:TPST)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

May 09, 2024 04:29 pm ET

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and...

Apr 26, 2024 04:05 pm ET

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of...

Apr 09, 2024 08:00 am ET

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center...

Apr 04, 2024 08:00 am ET

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Cancer Research Communications published positive clinical...

Mar 19, 2024 04:25 pm ET

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 14, 2024 03:56 pm ET

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors’ and officers’ possible violations of state laws.

Mar 12, 2024 08:00 am ET

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced a poster presentation at the Society for Immunotherapy of Cancer...

Mar 05, 2024 04:30 pm ET

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical Center...

Feb 26, 2024 08:00 am ET

Tempest to Present at the 44th Annual TD Cowen Healthcare Conference

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Stephen Brady, president and chief executive officer of...

Feb 02, 2024 04:30 pm ET

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that the Compensation Committee of the Company’s Board...

Jan 30, 2024 08:31 am ET

Thinking about buying stock in Agape ATP, Tempest Therapeutics, Nu Holdings, Bristol-Myers Squibb, or Petros Pharmaceuticals?

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATPC, TPST, NU, BMY, and PTPI.

Jan 05, 2024 04:05 pm ET

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that on January 3, 2024 the Compensation Committee of...

Dec 01, 2023 04:15 pm ET

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 27, 2023 08:31 am ET

Thinking about buying stock in Turnstone Biologics, Iterum Therapeutics, New Gold, GeneDx Holdings, or Tempest Therapeutics?

NEW YORK, Nov. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSBX, ITRM, NGD, WGS, and TPST.

Nov 20, 2023 08:00 am ET

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside chat at...

Nov 08, 2023 05:17 pm ET

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the third quarter ended September...

Nov 07, 2023 08:31 am ET

Thinking about buying stock in Applied Therapeutics, Coherus Biosciences, Tempest Therapeutics, Bluegreen Vacations Holding, or Adams Resources & Energy?

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APLT, CHRS, TPST, BVH, and AE.

Nov 02, 2023 09:31 am ET

Thinking about buying stock in Cybin, Intuitive Machines, Tempest Therapeutics, Plug Power, or OmniLit Acquisition?

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CYBN, LUNR, TPST, PLUG, and OLIT.

Oct 31, 2023 09:31 am ET

Thinking about buying stock in Tempest Therapeutics, Applied Digital, Ford Motor, Lockheed Martin, or Motus GI Holdings?

NEW YORK, Oct. 31, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPST, APLD, F, LMT, and MOTS.

Oct 23, 2023 09:31 am ET

Thinking about buying stock in XORTX Therapeutics, Tempest Therapeutics, Ginkgo Bioworks Holdings, Athersys, or Textainer Group Holdings?

NEW YORK, Oct. 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XRTX, TPST, DNA, ATHX, and TGH.

Oct 19, 2023 09:31 am ET

Thinking about buying stock in Tempest Therapeutics, Plug Power, Treasure Global, Firsthand Technology Value Fund, or NXU?

NEW YORK, Oct. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPST, PLUG, TGL, SVVC, and NXU.

Oct 18, 2023 09:31 am ET

Thinking about buying stock in Tempest Therapeutics, VinFast Auto, AGNC Investment, Ardelyx, or Viking Therapeutics?

NEW YORK, Oct. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPST, VFS, AGNC, ARDX, and VKTX.

Oct 13, 2023 09:31 am ET

Thinking about buying stock in Outset Medical, Tempest Therapeutics, Cassava Sciences, Rivian Automotive, or Athersys?

NEW YORK, Oct. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OM, TPST, SAVA, RIVN, and ATHX.

Oct 11, 2023 09:31 am ET

Thinking about buying stock in Beneficient, Femasys, Lucid Group, Tempest Therapeutics, or Ideanomics?

NEW YORK, Oct. 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BENF, FEMY, LCID, TPST, and IDEX.

Oct 11, 2023 08:01 am ET

Tempest Adopts Limited Duration Stockholder Rights Plan

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today announced that its Board of Directors (the “Board”) has adopted a...

Oct 11, 2023 08:00 am ET

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced new and updated positive results from the planned data...

Oct 10, 2023 04:05 pm ET

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the company plans to report new and updated data from...

Sep 19, 2023 08:00 am ET

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that executive vice president and chief medical officer,...

Sep 05, 2023 08:00 am ET

Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that Sam Whiting, M.D., Ph.D., chief medical officer of...

Aug 10, 2023 04:13 pm ET

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and...

Jul 19, 2023 08:00 am ET

Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that in vivo and in vitro data on the unique mechanism...

May 31, 2023 04:05 pm ET

Tempest to Present at the Jefferies Global Healthcare Conference

May 25, 2023 05:00 pm ET

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 25, 2023 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that Phase 1 clinical trial data for...

May 19, 2023 04:05 pm ET

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2023 04:15 pm ET

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023...

Apr 28, 2023 08:00 am ET

Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced positive early results from a global randomized Phase...

Apr 27, 2023 04:58 pm ET

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the company plans to report early data from its Phase...

Apr 26, 2023 06:41 pm ET

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2/EP4...

Apr 17, 2023 09:00 am ET

Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that new data from its TPST-1120 and TREX1 programs were...

Mar 22, 2023 05:26 pm ET

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the year ended December 31, 2022...

Mar 15, 2023 04:05 pm ET

Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting

Mar 14, 2023 04:30 pm ET

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Nov 22, 2022 04:05 pm ET

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside...

Nov 10, 2022 09:00 am ET

Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer

Nov 08, 2022 08:00 am ET

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended September 30,...

Nov 02, 2022 08:00 am ET

Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of two poster presentations, including a...

Oct 06, 2022 08:00 am ET

Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery...

Sep 07, 2022 08:00 am ET

Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 15, 2022 08:00 am ET

Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2022 and...

Jul 07, 2022 08:00 am ET

Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., will participate in a panel...

Jun 09, 2022 08:00 am ET

Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapies that combine both targeted and immune-mediated mechanisms, today summarized key takeaways from the TPST-1120 clinical program provided by Mark...

Jun 06, 2022 04:05 pm ET

Tempest to Present at the Jefferies Healthcare Conference

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the Jefferies Healthcare...

May 26, 2022 04:57 pm ET

Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapies that combine both targeted and immune-mediated mechanisms, today announced positive results from its Phase 1 clinical trial of TPST-1120, a...

May 13, 2022 08:00 am ET

Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2022...

Apr 27, 2022 10:01 am ET

Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapeutics that combine both targeted and immune-mediated mechanisms, today announced that two abstracts were accepted for presentation at the 2022 American...

Apr 27, 2022 08:00 am ET

Tempest Announces Private Placement Financing of $15 Million

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing novel therapeutics that combine both targeted and immune-mediated mechanisms, today announced a $15 million private investment in public equity (PIPE) financing...

Apr 08, 2022 01:00 pm ET

Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the presentation of two poster presentations...

Mar 29, 2022 04:00 pm ET

Tempest Reports Year End 2021 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the year ended December 31, 2021...

Mar 10, 2022 08:00 am ET

Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference

Mar 08, 2022 04:30 pm ET

Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Feb 09, 2022 08:00 am ET

Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference

Nov 18, 2021 08:00 am ET

Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both tumor-targeted and immune-mediated mechanisms, today announced the first patient has been dosed with...

Nov 12, 2021 07:00 am ET

Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer

Nov 10, 2021 04:05 pm ET

Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results and provided a corporate...

Nov 09, 2021 08:00 am ET

Tempest to Present at Two Upcoming Investor Conferences in November

Nov 08, 2021 08:00 am ET

Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced that the U.S. Patent and Trademark Office has...

Oct 01, 2021 08:00 am ET

Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Sep 20, 2021 08:00 am ET

Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche

Sep 13, 2021 08:00 am ET

Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target

Sep 09, 2021 04:01 pm ET

Tempest to Present at Upcoming Investor Conferences

Aug 12, 2021 04:01 pm ET

Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results and provided a corporate...

Aug 09, 2021 08:00 am ET

Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors

Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the appointment of Ronit...

Jul 15, 2021 09:31 am ET

Thinking about buying stock in Verb Technology, Casper Sleep, Millendo Therapeutics, Lipocine, or Hepion Pharmaceuticals?

NEW YORK, July 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, CSPR, TPST, LPCN, and HEPA.

Jul 13, 2021 08:30 am ET

Thinking about buying stock in Cemtrex, Millendo Therapeutics, Exela Technologies, OrganiGram, or electroCore?

NEW YORK, July 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CETX, TPST, XELA, OGI, and ECOR.

Jul 12, 2021 08:30 am ET

Thinking about buying stock in Tempest Therapeutics, Cemtrex, Exela Technologies, Aethlon Medical, or Bridgeline Digital?

NEW YORK, July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TPST, CETX, XELA, AEMD, and BLIN.

Jul 09, 2021 08:00 am ET

Ad blocking detected

Tempest Therapeutics Inc (OQ:TPST)

Business Focus: Biotechnology & Medical Research